PDE5A Suppresses Proteasome Activity Leading to Insulin Resistance in C2C12 Myotubes

Overview

Journal Int J Endocrinol

Publisher Wiley

Specialty Endocrinology

Date 2019 Feb 19

PMID 30774657

Citations 6

Authors

Wei Liu

Xiaojun Tian

Ti Wu

Le Liu

Yanghongyun Guo

Changhua Wang

Affiliations

Soon will be listed here.

Abstract

Objective: The involvement of phosphodiesterase type 5 (PDE5) in the development of insulin resistance has been reported recently. However, the underlying molecular mechanism remains unclear. The present study aims at investigating the potential impacts of PDE5A on insulin signaling in C2C12 skeletal muscle myotubes and uncover the related mechanism.

Methods: C2C12 myoblasts were differentiated into myotubes. Western blot was performed to detect the levels of proteins and phosphorylated proteins. Glucose uptake was determined by a colorimetric kit. The overexpression or knockdown of specific protein was carried out by infecting the myotubes with adenoviruses carrying cDNA or shRNA corresponding to the targeted protein, respectively.

Results: PDE5A was demonstrated to negatively regulate insulin signaling, evidenced by the opposite effects on the suppression or enhancement of the insulin-stimulated Akt phosphorylation and 2-deoxy-D-glucose (2-DG) uptake in C2C12 myotubes, when PDE5A was overexpressed or knockdown, respectively. Interestingly, PDE5A overexpression led to significantly enhanced, while its knockdown resulted in markedly reduced, endoplasmic reticulum (ER) stress. Inhibition of ER stress improved PDE5A overexpression-induced insulin resistance. In addition, PDE5A was found to suppress proteasome activity. Inhibition of PDE5 by its selective inhibitor icariin restored PDE5A overexpression-reduced proteasome activity and mitigated PDE5A overexpression-induced ER stress. Consistently, icariin administration also markedly attenuated the detrimental impacts of PDE5A overexpression on insulin signaling.

Conclusions: These results suggest that PDE5A suppresses proteasome activity, which results in ER stress and subsequent insulin resistance in C2C12 myotubes.

Citing Articles

Icariin has the potential to induce the differentiation of bone marrow mesenchymal stem cells into brown fat cells via PDE5A inhibition.

Lu Y, Xu X, Liu S, Wang Z, Jiang K, Gu J Heliyon. 2023; 9(12):e22487.

PMID: 38094047 PMC: 10716507. DOI: 10.1016/j.heliyon.2023.e22487.

Retraction: APPL1-Mediating Leptin Signaling Contributes to Proliferation and Migration of Cancer Cells.

PLoS One. 2023; 18(3):e0283346.

PMID: 36920975 PMC: 10016670. DOI: 10.1371/journal.pone.0283346.

A human-based multi-gene signature enables quantitative drug repurposing for metabolic disease.

Timmons J, Anighoro A, Brogan R, Stahl J, Wahlestedt C, Farquhar D Elife. 2022; 11.

PMID: 35037854 PMC: 8763401. DOI: 10.7554/eLife.68832.

Single-Cell Transcriptional Profiling of Mouse Islets Following Short-Term Obesogenic Dietary Intervention.

Pineros A, Gao H, Wu W, Liu Y, Tersey S, Mirmira R Metabolites. 2020; 10(12).

PMID: 33353164 PMC: 7765825. DOI: 10.3390/metabo10120513.

Advantages of Phosphodiesterase Type 5 Inhibitors in the Management of Glucose Metabolism Disorders: A Clinical and Translational Issue.

Antinozzi C, Sgro P, Di Luigi L Int J Endocrinol. 2020; 2020:7078108.

PMID: 32774364 PMC: 7407035. DOI: 10.1155/2020/7078108.

References

Conejo R, Valverde A, Benito M, Lorenzo M . Insulin produces myogenesis in C2C12 myoblasts by induction of NF-kappaB and downregulation of AP-1 activities. J Cell Physiol. 2001; 186(1):82-94. DOI: 10.1002/1097-4652(200101)186:1<82::AID-JCP1001>3.0.CO;2-R. View

Rotella D . Phosphodiesterase 5 inhibitors: current status and potential applications. Nat Rev Drug Discov. 2002; 1(9):674-82. DOI: 10.1038/nrd893. View

Xin Z, Kim E, Lin C, Liu W, Tian L, Yuan Y . Effects of icariin on cGMP-specific PDE5 and cAMP-specific PDE4 activities. Asian J Androl. 2003; 5(1):15-8. View

Ozcan U, Cao Q, Yilmaz E, Lee A, Iwakoshi N, Ozdelen E . Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science. 2004; 306(5695):457-61. DOI: 10.1126/science.1103160. View

Fujita E, Kouroku Y, Isoai A, Kumagai H, Misutani A, Matsuda C . Two endoplasmic reticulum-associated degradation (ERAD) systems for the novel variant of the mutant dysferlin: ubiquitin/proteasome ERAD(I) and autophagy/lysosome ERAD(II). Hum Mol Genet. 2007; 16(6):618-29. DOI: 10.1093/hmg/ddm002. View

Kondratyev M, Avezov E, Shenkman M, Groisman B, Lederkremer G . PERK-dependent compartmentalization of ERAD and unfolded protein response machineries during ER stress. Exp Cell Res. 2007; 313(16):3395-407. DOI: 10.1016/j.yexcr.2007.07.006. View

Zhang M, Koitabashi N, Nagayama T, Rambaran R, Feng N, Takimoto E . Expression, activity, and pro-hypertrophic effects of PDE5A in cardiac myocytes. Cell Signal. 2008; 20(12):2231-6. PMC: 2601628. DOI: 10.1016/j.cellsig.2008.08.012. View

Rahimi R, Ghiasi S, Azimi H, Fakhari S, Abdollahi M . A review of the herbal phosphodiesterase inhibitors; future perspective of new drugs. Cytokine. 2009; 49(2):123-9. DOI: 10.1016/j.cyto.2009.11.005. View

Papandreou I, Denko N, Olson M, Van Melckebeke H, Lust S, Tam A . Identification of an Ire1alpha endonuclease specific inhibitor with cytotoxic activity against human multiple myeloma. Blood. 2010; 117(4):1311-4. PMC: 3056474. DOI: 10.1182/blood-2010-08-303099. View

10.

Mammi C, Pastore D, Lombardo M, Ferrelli F, Caprio M, Consoli C . Sildenafil reduces insulin-resistance in human endothelial cells. PLoS One. 2011; 6(1):e14542. PMC: 3030559. DOI: 10.1371/journal.pone.0014542. View

11.

Aversa A . Systemic and metabolic effects of PDE5-inhibitor drugs. World J Diabetes. 2011; 1(1):3-7. PMC: 3083877. DOI: 10.4239/wjd.v1.i1.3. View

12.

Sabatini S, Sgro P, Duranti G, Ceci R, Di Luigi L . Tadalafil alters energy metabolism in C2C12 skeletal muscle cells. Acta Biochim Pol. 2011; 58(2):237-41. View

13.

Armani A, Marzolla V, Rosano G, Fabbri A, Caprio M . Phosphodiesterase type 5 (PDE5) in the adipocyte: a novel player in fat metabolism?. Trends Endocrinol Metab. 2011; 22(10):404-11. DOI: 10.1016/j.tem.2011.05.004. View

14.

Zhu D, Cui R, Zhang Y, Li H, Zhou L, Lou Y . Involvement of ubiquitin-proteasome system in icariin-induced cardiomyocyte differentiation of embryonic stem cells using two-dimensional gel electrophoresis. J Cell Biochem. 2011; 112(11):3343-53. DOI: 10.1002/jcb.23264. View

15.

Ranek M, Terpstra E, Li J, Kass D, Wang X . Protein kinase g positively regulates proteasome-mediated degradation of misfolded proteins. Circulation. 2013; 128(4):365-76. PMC: 3761383. DOI: 10.1161/CIRCULATIONAHA.113.001971. View

16.

Crescioli C, Sturli N, Sottili M, Bonini P, Lenzi A, Di Luigi L . Insulin-like effect of the phosphodiesterase type 5 inhibitor tadalafil onto male human skeletal muscle cells. J Endocrinol Invest. 2013; 36(11):1020-6. DOI: 10.3275/9034. View

17.

Chrysant S . Effectiveness and safety of phosphodiesterase 5 inhibitors in patients with cardiovascular disease and hypertension. Curr Hypertens Rep. 2013; 15(5):475-83. DOI: 10.1007/s11906-013-0377-9. View

18.

Gong W, Duan Q, Cai Z, Chen C, Ni L, Yan M . Chronic inhibition of cGMP-specific phosphodiesterase 5 suppresses endoplasmic reticulum stress in heart failure. Br J Pharmacol. 2013; 170(7):1396-409. PMC: 3838686. DOI: 10.1111/bph.12346. View

19.

Inagi R, Ishimoto Y, Nangaku M . Proteostasis in endoplasmic reticulum--new mechanisms in kidney disease. Nat Rev Nephrol. 2014; 10(7):369-78. DOI: 10.1038/nrneph.2014.67. View

20.

Hu H, Li L, Wang C, He H, Mao K, Ma X . 4-Phenylbutyric acid increases GLUT4 gene expression through suppression of HDAC5 but not endoplasmic reticulum stress. Cell Physiol Biochem. 2014; 33(6):1899-910. DOI: 10.1159/000362967. View